Australia is carefully awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://tamzinkfrg749787.wannawiki.com/1587268/novo_nordisk_s_retatrutide_australia_a_potential_solution_for_weight_management